Key Highlights
- MicroSalt lowered full-year 2026 sales guidance to around US$4.5 million, down from roughly US$7.0 million previously signalled.
- 2025 Revenue rose to about US$2.1 million, nearly tripling the roughly US$750,000 booked in 2024.
- The group remains loss-making and pre-profit, with a 2027 product-launch programme central to the growth thesis.
- Customer concentration and further funding needs remain key risks for the small AIM-listed business.
MicroSalt (LSE:SALT) has long been one of the more intriguing propositions on London's junior market: a company whose entire Investment case rests on the idea that consumers can keep the taste of salt while shedding much of the sodium that public-health bodies have spent years warning against. Every so often the shares attract a fresh wave of interest as investors revisit that low-sodium food-technology story. Anyone doing so in late August 2026 should balance a genuinely differentiated product against the reality of a small, still loss-making Business whose near-term commercial timetable has just been pushed back.
What the company actually does
MicroSalt, listed on AIM, has developed a patented process that mills salt into microscopic particles. Because those particles carry far more surface area than ordinary grains, more of the salt touches the tongue, so a comparable salty sensation can be achieved with considerably less sodium. The group monetises this in two ways: a business-to-business ingredient sold to manufacturers looking to reformulate crisps, snacks and seasonings, and a consumer-facing brand, SaltMe!, sold through retail and online channels. Management's central argument is that tightening regulation and health-conscious shoppers give reformulation a structural tailwind, with the higher-volume B2B channel the larger long-term prize and the branded range serving to prove the technology at retail.
Latest developments
The most material recent news was not, however, unambiguously positive. In a 2026 trading update MicroSalt lowered its full-year 2026 sales guidance to around US$4.5 million, from the roughly US$7.0 million it had signalled the previous November. The company framed the reduction as a timing issue, linking it to the production schedule around a 2027 product-launch programme rather than to any weakening in underlying demand. That followed a strong 2025, when revenue reached about US$2.1 million, nearly tripling the roughly US$750,000 booked in 2024, helped by reformulation work with large snack-food manufacturers. The direction of travel on sales is upward; the pace has proved lumpy and hard to forecast. The gap between the earlier US$7.0 million signal and the revised US$4.5 million figure is a reminder of how sensitive a company at this stage is to the timing of a small number of large manufacturer decisions, and of how much weight the market is placing on the 2027 launch programme to deliver the step-change in volumes that has so far been talked about rather than banked.
Financials, funding and risks
For investors the tension is familiar for early-stage food-technology names. Revenue is growing quickly from a low base, but the group remains loss-making and its progress depends on converting trials and reformulation projects into repeat commercial volumes. That makes customer concentration a genuine consideration: a handful of large manufacturer contracts could transform the numbers, yet a delay at any one of them feeds straight through to guidance, as the latest downgrade shows.
As with most pre-profit AIM companies, the capacity to fund the business through to sustained cash generation matters as much as the product itself. Investors should assume the shares remain sensitive to any need for further Capital and the attendant risk of dilution, as well as to execution on the 2027 launch plan and to the thin Liquidity typical of a micro-cap, which can exaggerate share-price moves on limited news.
What investors may watch next
Potential catalysts from here include confirmation of named manufacturer roll-outs, evidence that the 2027 launch schedule is on track, and signs that the B2B pipeline is converting into recurring orders rather than one-off trials. The key question is whether MicroSalt (LSE:SALT) can turn a compelling health narrative and rising, if volatile, revenue into a self-sustaining business. Until then the story is likely to stay speculative, and the shares could continue to swing on each fresh data point about timing and Demand rather than on any settled view of the technology's long-run potential.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...